Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.62 |
| ▸ | CTSS | P25774 | 4/20 | 0.57 |
| ▸ | CTSL | P07711 | 3/20 | 0.57 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | PYGL | P06737 | 1/20 | 0.48 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25238203 | 1.00 | TAS1R3 (0.62) | TAS1R3TAS1R1CTSSCTSLCTSK | |
| SCHEMBL10784947 | 0.83 | TAS1R3 (0.67) | TAS1R3TAS1R1CTSSCTSLCTSK | |
| SCHEMBL25289636 | 0.83 | CTSL (0.56) | CTSSCTSL | |
| SCHEMBL25289637 | 0.83 | CTSL (0.56) | CTSSCTSL | |
| SCHEMBL25287270 | 0.83 | TAS1R3 (0.70) | TAS1R3TAS1R1CTSSCTSLCTSK | |
| SCHEMBL25244832 | 0.83 | TAS1R3 (0.70) | TAS1R3TAS1R1CTSSCTSLCTSK | |
| SCHEMBL25286173 | 0.83 | TAS1R3 (0.73) | TAS1R3TAS1R1CTSSCTSLCTSK | |
| SCHEMBL25244468 | 0.83 | TAS1R3 (0.73) | TAS1R3TAS1R1CTSSCTSLCTSK | |
| SCHEMBL25286876 | 0.81 | TAS1R3 (0.56) | TAS1R3TAS1R1CTSSCTSLCTSK | |
| SCHEMBL25243875 | 0.81 | TAS1R3 (0.56) | TAS1R3TAS1R1CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060333-B2 | Aminocarbamoyl compounds for the treatment of viral infections | HOFFMANN-LA ROCHE INC. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-116438160-A | Carbamoyl compounds for the treatment of viral infections | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4204393-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060333-B2 | Aminocarbamoyl compounds for the treatment of viral infections | SARS1, BCAT1, SLC1A5 | TAS1R3 2062/4885TAS1R1 1564/4885CTSS 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.